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Clinical Trials
Oxypurinol May Benefit
Congestive Heart Failure Patients With High Uric Acid
Xanthine oxidase (XO) is elevated in heart failure and contributes to vasoconstric-tion and myocardial dysfunction. The OPT-CHF trial randomized over 400
class III to IV heart failure patients to either the XO inhibitor, oxypurinol, or placebo,
and followed them for 24 weeks with a composite end point comprising morbidity,
mortality, andquality of life.When all subjectswere included, therewere no significant
differences between oxypurinol and placebo. However, those subjects with elevated
baseline uric acid (9.5 mg/dl) did benefit, while those with low or normal uric acid
levels worsened. Oxypurinol is not useful in unselected patients with class III to IV
heart failure, but may be beneficial in those with elevated uric acid levels. See pages
2301 and 2310. See figure.
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Coronary Artery Surgery
No Evidence of Widespread Inappropriate CABG Surgery
There is substantial geographic variability in the population-based rates of coronaryartery bypass graft (CABG) surgery, but the rate of inappropriate CABG is
unknown. O’Connor and colleagues used the American College of Cardiology/
American Heart Association 2004 guidelines to classify the appropriateness of
nearly 5,000 CABG surgeries from 8 hospitals: Class I (useful and effective),
Class II, or Class III (not useful or effective). The vast majority of procedures
were Class I (88%). Class II procedures totaled 11%, and the remaining 1.4%
procedures were Class III. In this regional study, 98.6% of CABG procedures
were considered to be appropriate by published guidelines. See page 2323.
See figure.
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Heart Failure
BNP Useful for Stratifying Stable Heart Failure Patients
Nishii and colleagues studied the utility of measuring B-type natriuretic peptide(BNP) inpatientswithnon-ischemicdilated cardiomyopathy (NICM)whohad
been stable and asymptomatic for at least 6 months. The main end point was
rehospitalization or death over the next 18 months. The risk of rehospitalization or
death increased with higher BNP levels; the hazard ratios for those with BNPs 190 to
380 pg/ml and380 pg/ml were 5 and 11.5, respectively, compared with those with
a BNP190 pg/ml. These results show that in stable, apparently low-risk outpatients
with NICM, the BNP level 6 months after hospital discharge predicts the long-term
risk of decompensation. See pages 2329 and 2336. See figure.
(continued) A-24Biomarkers
CRP Level Does Not Predict Outcomes Post-ACS
Elevated inflammatory markers may reflect a more active atherosclerotic substrateand thereby identify patients at increased risk. Bogaty and colleagues measured
C-reactive protein (CRP) at hospital admission, discharge, and1month after discharge
from over 1,200 patients with acute coronary syndomes (ACS). The primary outcome
was a composite of death andACS over the next year. The unadjusted odds ratios were
weakly positive for CRP values at admission and 1 month, but not at hospital
discharge. After adjusting for age, heart failure symptoms, diabetes, and electrocardio-
gram changes, CRP levels added no further predictive information. The modest
predictive ability ofCRP following admission for anACSdisappears after adjusting for
common clinical variables. See page 2339.
